On April 20, 2017 TG Therapeutics, Inc. (NASDAQ:TGTX), reported that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the upcoming 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), to be held from June 2 – 6, 2017, at McCormick Place in Chicago, Illinois (Press release, TG Therapeutics, APR 20, 2017, View Source [SID1234518652]). Details of the data presentations are outlined below. Schedule your 30 min Free 1stOncology Demo! Oral Presentation:
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study
Abstract Number: 7504
Presentation Date & Time: Saturday, June 3, 2017 3:00 PM – 6:00 PM CT
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Jeffrey P. Sharman, MD
Poster Discussion Presentation:
Title: Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL
Abstract Number: 7511
Presentation Date & Time: Monday, June 5, 2017 8:00 AM-11:30 AM CT (Poster Viewing); 1:15 PM-2:30 PM CT (Poster Discussion)
Session Title: Poster Discussion Session, Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Loretta Nastoupil, MD
Trials in Progress Poster Presentation:
Title: KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy
Abstract Number: TPS7569
Presentation Date & Time: Monday, June 5, 2017 8:00 AM-11:30 AM CT
Session Title: Poster Session, Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Colleen Dorsey, BSN, RN
The above abstracts will be released publicly on May 17, 2017 through the ASCO (Free ASCO Whitepaper) meeting website at www.asco.org. Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com.